Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.
Two new FDA approvals for patients with multiple myeloma – isatuximab (Sarclisa) and daratumumab (Darzalex) – were practice changing for 2020, according to Peter Voorhees, MD, of the Levine Cancer Institute.
In an interview with CancerNetwork, Voorhees noted that despite the many challenges that arose in 2020, immense progress was made for patients with multiple myeloma, both in the frontline and relapsed/refractory setting.
I would say that in spite of the [coronavirus disease 2019 (COVID-19)] pandemic, there's been tremendous progress in the field of multiple myeloma.
I think the addition of the CD38 monoclonal antibodies into frontline therapy and newly diagnosed myeloma patients has changed practice. I think that the immunotherapies that are being developed in relapsed and refractory multiple myeloma patients are highly promising and continue to show significant activity in patients who have triple-class refractory disease. The studies are ongoing, many of them will be presented at this year's ASH, so in spite of very trying circumstances, we continue to make considerable progress against this disease.